Information For the Use Methylergometrine (0.125mg)

Utilair 0.125 Injection

$\begin{array}{l} \textbf{Methylergometrine} \ (0.125 \ \mathrm{mg}) \\ \textbf{Injection} \end{array}$

Generic Name:

Methylergometrine maleate

Strength:

0.125 mg/mL

Formulation:

Sterile solution for **intramuscular (IM)** or **intravenous (IV)** injection

Uses:

- Prevention and treatment of postpartum hemorrhage (excessive bleeding after childbirth)
- Helps the uterus contract to control and minimize blood loss after delivery

Mechanism of Action:

Methylergometrine is an **ergot derivative** that directly stimulates uterine smooth muscle, causing sustained contractions and reducing bleeding.

Dosage:

- Typical Dose: 0.125 mg via intramuscular (IM) or slow intravenous (IV) injection
- Can be repeated every **2-4 hours** as needed, up to a maximum of **5 doses**
- Administer under healthcare supervision only

Precautions:

- Not for use during pregnancy
- Avoid if you have:
 - Hypertension
 - Heart disease
 - Liver or kidney issues
- Caution when breastfeeding (consult your healthcare provider)

Side Effects:

- Common:
 - Nausea or vomiting
 - Headache
 - o Abdominal pain
- Severe:
 - o Sudden high blood pressure
 - o Chest pain
 - o Difficulty breathing

Seek **immediate medical attention** if severe symptoms occur.

Administration Guidelines:

- Intravenous administration should be slow (over at least 60 seconds) to prevent sudden hypertension.
- Use aseptic technique to avoid contamination.

Storage:

- Store at 20°C to 25°C (68°F to 77°F)
- Protect from light
- Do not freeze
- Keep out of reach of children

Note:

Methylergometrine injection should be administered only by a **qualified healthcare professional** to ensure safety and efficacy.

Manufactured in India for:



(An ISO 9001: 2015 Certified Co.) Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for